Physician profile
Mason Jahnke
NPI 1457767246
$4,677.03
in general payments reported to CMS, 2019-2025
15 companies · $863 in 2025
The $863 reported for 2025 was more than what 79% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $558 · 2020: $125 · 2021: $182 · 2022: $1,095 · 2023: $1,149 · 2024: $706 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,027.89 | 2021-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Alkermes, INC. | $830.43 | 2019-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $623.78 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $527.51 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Abbvie INC. | $449.34 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $275.77 | 2022-2025 | Uzedy |
| Allergan, INC. | $249.84 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $208.94 | 2021-2025 | Caplyta |
| Indivior INC. | $178.91 | 2022-2023 | Perseris |
| Avanir Pharmaceuticals, INC. | $124.99 | 2019 | |
| Lundbeck LLC | $69.93 | 2022-2023 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $40.74 | 2025 | Cobenfy |
| Axsome Therapeutics, INC. | $31.00 | 2022-2024 | Auvelity |
| Vanda Pharmaceuticals INC. | $21.35 | 2024 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $16.61 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mason Jahnke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.